ArticleTissue engineering. Part A2020
Evaluation of Autologously Derived Biomaterials and Stem Cells for Bone Tissue Engineering.
Article in Tissue engineering. Part A, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
8 citing papers in PubMed.
- Enhanced decellularization of human amniotic membrane: optimizing dna clearance and protein retention for clinical applications.Molecular biology reports · 2026Article
- FIBER DIAMETER-DRIVEN MODULATION OF CELL BEHAVIOR IN DECM-ENRICHED ELECTROSPUN SCAFFOLDS FOR BONE TISSUE ENGINEERING.International journal of high speed electronics · 2026Article
- Towards Safety and Regulation Criteria for Clinical Applications of Decellularized Organ-Derived Matrices.Bioengineering (Basel, Switzerland) · 2025Review
- Engineering bone/cartilage organoids: strategy, progress, and application.Bone research · 2024Review
- Decellularized Tissue-Induced Cellular Recruitment for Tissue Engineering and Regenerative Medicine.Annals of biomedical engineering · 2024Article
- Decellularized extracellular matrix biomaterials for regenerative therapies: Advances, challenges and clinical prospects.Bioactive materials · 2024Review
- Amorphous silica fiber matrix biomaterials: An analysis of material synthesis and characterization for tissue engineering.Bioactive materials · 2023Article
- Bio-inspired zonal-structured matrices for bone-cartilage interface engineering.Biofabrication · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Despite progress, clinical translation of tissue engineering (TE) products/technologies is limited. A significant effort is underway to develop biomaterials and cells through a minimally modified process for clinical translation of TE products. Recently, bone marrow aspirate (BMA) was identified as an autologous source of cells for TE applications and is currently being tested in clinical therapies, but the isolation methods need improvement to avoid potential for contamination and increase progenitor cell yield. To address these issues, we reproducibly processed human peripheral blood (PB) and BMA to develop autologously derived biomaterials and cells. We demonstrated PB-derived biomaterial/gel cross-linking and fibrin gel formation with varied gelation times as well as biocompatibility through support of human bone marrow-derived stem cell survival and growth
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.